CSIMarket
 


Diamedica Therapeutics Inc   (DMAC)
Other Ticker:  
 
 

DMAC's Income from Cont. Operations Growth by Quarter and Year

Diamedica Therapeutics Inc 's Income from Cont. Operations results by quarter and year




DMAC Income from Cont. Operations (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December -5.16 -3.75 -3.25 -4.20
III Quarter September -4.47 -3.06 -3.45 -3.19
II Quarter June -4.48 -3.36 -3.27 -2.47
I Quarter March -5.27 -3.51 -3.62 -2.43
FY   -19.38 -13.68 -13.59 -12.29



DMAC Income from Cont. Operations fourth quarter 2023 Y/Y Growth Comment
Diamedica Therapeutics Inc in the fourth quarter 2023 recorded loss from continued operations of $ -5.16 millions.

According to the results reported in the fourth quarter 2023, Diamedica Therapeutics Inc achieved the best Income from Cont. Operations growth in Major Pharmaceutical Preparations industry. While Diamedica Therapeutics Inc ' s Income from Cont. Operations no change of % ranks overall at the positon no. in the fourth quarter 2023.




DMAC Income from Cont. Operations ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   - - - -

Financial Statements
Diamedica Therapeutics Inc 's fourth quarter 2023 Income from Cont. Operations $ -5.16 millions DMAC's Income Statement
Diamedica Therapeutics Inc 's fourth quarter 2022 Income from Cont. Operations $ -3.75 millions Quarterly DMAC's Income Statement
New: More DMAC's historic Income from Cont. Operations Growth >>


DMAC Income from Cont. Operations (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY (Year on Year)   - - - -




Income from Cont. Operations fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Income from Cont. Operations fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Income from Cont. Operations by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Diamedica Therapeutics Inc 's Q/Q Income from Cont. Operations Growth


Income from Cont. Operations Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


DMAC's IV. Quarter Q/Q Income from Cont. Operations Comment
IV. Quarter 2023 results of -5.16 millions by Diamedica Therapeutics Inc come out even less good if you take a look at -4.47 millions a quarter before.

Within Major Pharmaceutical Preparations industry Diamedica Therapeutics Inc achieved highest sequential Income from Cont. Operations growth. While Diamedica Therapeutics Inc 's Income from Cont. Operations growth quarter on quarter, overall rank is .


Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


DMAC's IV. Quarter Q/Q Income from Cont. Operations Comment
IV. Quarter 2023 loss from continued operations of -5.16 millions by Diamedica Therapeutics Inc look even less good considering the -4.47 millions loss from continued operations a quarter before.

Within Major Pharmaceutical Preparations industry Diamedica Therapeutics Inc achieved highest sequential Income from Cont. Operations growth. While Diamedica Therapeutics Inc 's Income from Cont. Operations growth quarter on quarter, overall rank is .


Diamedica Therapeutics Inc 's 12 Months Income from Cont. Operations Growth Year on Year


Income from Cont. Operations TTM Growth

12 Months Ending
(Dec 31 2023)
12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
Cumulative Income from Cont. Operations 12 Months Ending $ -19.38 $ -17.97 $ -16.56 $ -15.44 $ -13.68
Y / Y Income from Cont. Operations Growth (TTM) - - - - -
Year on Year Income from Cont. Operations Growth Overall Ranking # # # # #
Seqeuential Income from Cont. Operations Change (TTM) - - - - -
Seq. Income from Cont. Operations Growth (TTM) Overall Ranking # # # # #




Cumulative Income from Cont. Operations growth Comment
Diamedica Therapeutics Inc ' has realized cumulative trailing twelve months loss from continued operations of $ -19 millions in the Dec 31 2023 period.
The situation is detiriorating as the cumulative loss from continued operations is getting bigger from $ -17.97 millions in TTM ending quarter Sep 30 2023 and $ -13.171 millions for the twelve months ending in the quarter Dec 31 2022.

Diamedica Therapeutics Inc achieved highest trailing twelve month year on year Income from Cont. Operations growth. While overall Income from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Income from Cont. Operations growth Comment
Diamedica Therapeutics Inc ' has realized cumulative trailing twelve months loss from continued operations of $ -19 millions in the Dec 31 2023 period.
The situation is detiriorating as the cumulative loss from continued operations is inflating from $ -17.97 millions in TTM ending quarter Sep 30 2023 and $ -13.171 millions from the TTM period ending Dec 31 2022.

Diamedica Therapeutics Inc achieved highest trailing twelve month year on year Income from Cont. Operations growth. While overall Income from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Income from Cont. Operations Growth
Major Pharmaceutical Preparations Industry Income from Cont. Operations Growth Trends and Statistics
Healthcare Sector Income from Cont. Operations Growth Statistics
Income from Cont. Operations Growth Trends for overall market
DMAC's Income from Cont. Operations Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Income from Cont. Operations Growth
Lowest Ranking Income from Cont. Operations Growth
Income from Cont. Operations Growth for DMAC's Competitors
Income from Cont. Operations Growth for Diamedica Therapeutics Inc 's Suppliers
Income from Cont. Operations Growth for DMAC's Customers

You may also want to know
DMAC's Annual Growth Rates DMAC's Profitability Ratios DMAC's Asset Turnover Ratio DMAC's Dividend Growth
DMAC's Roe DMAC's Valuation Ratios DMAC's Financial Strength Ratios DMAC's Dividend Payout Ratio
DMAC's Roa DMAC's Inventory Turnover Ratio DMAC's Growth Rates DMAC's Dividend Comparisons



Companies with similar Income from Cont. Operations no change for the quarter ending Dec 31 2023 within Healthcare SectorY/Y Change %Income from Cont. Operations for the quarter ending Dec 31 2023
Cytek Biosciences Inc 64.76%$ 64.760 millions
United Therapeutics Corporation64.35%$ 64.345 millions
Fonar Corporation64.30%$ 64.296 millions
Select Medical Holdings Corp63.87%$ 63.868 millions
Abbott Laboratories54.31%$ 54.308 millions
Integer Holdings Corporation54.22%$ 54.225 millions
Lemaitre Vascular Inc 50.44%$ 50.435 millions
Encompass Health Corporation49.94%$ 49.941 millions
Msa Safety Incorporated48.40%$ 48.401 millions
Halozyme Therapeutics Inc 47.98%$ 47.981 millions
Cadre Holdings Inc 45.39%$ 45.386 millions
Chemed Corporation44.95%$ 44.952 millions
Viemed Healthcare Inc 42.62%$ 42.617 millions
Healthcare Services Group Inc 39.85%$ 39.848 millions
Ufp Technologies Inc 37.18%$ 37.178 millions
Catalyst Pharmaceuticals Inc 36.80%$ 36.799 millions
National Research Corporation33.38%$ 33.384 millions
West Pharmaceutical Services Inc 33.01%$ 33.010 millions
Hologic Inc31.54%$ 31.537 millions
Semler Scientific Inc 31.25%$ 31.250 millions
Takeda Pharmaceutical Company Limited30.34%$ 30.344 millions
Orasure Technologies Inc28.99%$ 28.987 millions
Tenax Therapeutics Inc 26.55%$ 26.554 millions
Conmed Corporation24.40%$ 24.402 millions
The Pennant Group Inc 22.84%$ 22.837 millions
Inmode Ltd 22.54%$ 22.535 millions
Option Care Health Inc 20.30%$ 20.299 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com